Tanun Ngamvichchukorn

Tanun Ngamvichchukorn

Auto-generated profile, based on publicly available information

Tanun Ngamvichchukorn

Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; Division of Nephrology, Department of Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Blood Purification
Verified
Journal Article
Open access
PDF file
WPWanjak Pongsittisak Wanjak Pongsittisak
Wanjak Pongsittisak Wanjak Pongsittisak
PSPanchalee Satpanich
Panchalee Satpanich
SJSolos Jaturapisanukul
Solos Jaturapisanukul
RKRassamon Keawvichit
Rassamon Keawvichit
SPSurazee Prommool
Surazee Prommool
SKSathit Kurathong
Sathit Kurathong
Introduction: The coronavirus disease 2019 (COVID-19) pandemic has caused extensive morbidity and mortality worldwide. Hemodialysis (HD) patients are both vulnerable to COVID-19 infection and tend to suffer greater disease severity and mortality. This retrospective study aimed to compare medium cut-off (MCO) and low-flux (LF) membrane dialyzers in terms of interleukin-6 (IL-6) reduction, change in inflammatory state, intradialytic complications, and mortality in chronic HD patients with COVID-19. Method: HD patients with a confirmed COVID-19 infection were admitted to the hospital for 10–14 days and underwent HD at the COVID-HD unit. Choice of dialyzer membrane used (MCO vs. LF) depended on the primary nephrologist(s). We collected data on demographics, baseline characteristics, laboratory results, diagnosis, treatments, HD prescription, hemodynamic status during HD, and mortality at 14 and 28 days after. Results: IL-6 reduction ratio (RR) in the MCO group was 9.7 (interquartile range, 71.1) percent, which was significantly higher than that of the LF group (RR, −45.7 [interquartile range, 70.2] percent). The incidence rate of intradialytic hypotension in the MCO group was 3.846 events per 100 dialysis hours (95% confidence interval [CI], 1.954–6.856), which was significantly lower than that of the LF group (9.057; 95% CI, 5.592–13.170). Overall, mortality was not significantly different between the two groups. Conclusion: The MCO membrane was more effective in removing IL-6 and was better tolerated than the LF membrane. Large, randomized controlled trials are required to confirm the relative benefits of the MCO membrane, especially mortality. However, due to the COVID-19 pandemic, our results suggest that the MCO membrane may be beneficial in chronic HD patients with COVID-19.


1 August 2025 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
PSPiboon Showtanapanich
Piboon Showtanapanich
CPChadawan Pathonsmith
Chadawan Pathonsmith
JSJiraporn Sri-On
Jiraporn Sri-On
AJAppasornsawan Jatutain
Appasornsawan Jatutain
TNTanun Ngamvichchukorn
Tanun Ngamvichchukorn
Background: Residual kidney function (RKF) plays a crucial role in maintaining biochemical balance in hemodialysis patients. Frailty, commonly observed in end-stage renal disease (ESRD) patients, is associated with metabolic derangements, inflammation, and fluid overload. However, the relationship between RKF and frailty in this population remains unclear. Purpose: This study aimed to investigate the association between RKF and frailty in ESRD patients undergoing hemodialysis. Secondary objectives included assessing the prevalence of frailty and sarcopenia, and identifying clinical correlates. Patients and Methods: A cross-sectional study was conducted involving 110 adult ESRD patients undergoing maintenance hemodialysis for ≥ 6 months at an urban teaching hospital in Bangkok, Thailand between October 2023 and February 2024. RKF was assessed by 24-hour urine volume, with < 100 mL defined as absent RKF. Frailty was evaluated using the Thai version of the FRAIL scale, and sarcopenia was diagnosed based on the 2019 Asian Working Group for Sarcopenia (AWGS) criteria. Demographic, clinical, and laboratory data were analyzed using chi-squared tests, logistic regression, and multivariable models. Results: Among 110 participants, 78 (70.91%) had no RKF. Frailty prevalence was 13.64%, and sarcopenia prevalence was 65.45%. Frailty was associated with a history of cerebrovascular accident [adjusted odds ratio (OR) 10.303; P = 0.036] and lower total iron-binding capacity (TIBC) (adjusted OR 0.972; P = 0.047). Sarcopenia was linked to advanced age (adjusted OR 1.054; P = 0.020) and lower Kt/V values (adjusted OR 0.417; P = 0.002). RKF was not significantly associated with frailty. Conclusion: While RKF was not directly associated with frailty, this study highlights other significant factors, such as cerebrovascular accidents and low TIBC, contributing to frailty and advanced age associated with sarcopenia. These findings emphasize the need for comprehensive frailty screening and tailored interventions to improve outcomes in ESRD patients.

30 September 2026 in Nephrology
Verified
Journal Article
Open access
PDF file
SUSuwasin Udomkarnjananun
Suwasin Udomkarnjananun
NSNapun Sutharattanapong
Napun Sutharattanapong
NLNuttasith Larpparisuth
Nuttasith Larpparisuth
KPKorntip Phonphok
Korntip Phonphok
TNTanun Ngamvichchukorn
Tanun Ngamvichchukorn
TSThai Transplantation Society
Thai Transplantation Society
The Thai Transplantation Society developed these clinical practice guidelines to establish a comprehensive standard for immunosuppressive therapy in adult kidney transplantation. While rooted in evidence‐based medicine, the objective of this document extends beyond local application, serving as a practical model for low‐to‐middle‐income countries, particularly within the Asia‐Pacific and Southeast Asian regions, where specific genetic profiles and resource limitations require tailored management strategies. This publication addresses a critical need in the field, as there has been no updated comprehensive international consensus on immunosuppression since the KDIGO Clinical Practice Guideline in 2009, over 17 years ago. These guidelines bridge this gap by synthesizing modern clinical data with practical applicability. The scope of the guidelines is extensive, covering all aspects of immunosuppression usage including induction, maintenance, therapeutic drug monitoring, and the treatment of rejection. Uniquely, this document addresses specific challenges relevant to resource‐limited settings, offering protocols for cost reduction through the use of generic drugs and the co‐administration of cytochrome P450 3A4 and 3A5 inhibitors to minimize dosage requirements. Furthermore, it provides distinct guidance for immunosuppression in special clinical settings, including management during periods of fasting, pregnancy, and malignancy. This guideline ultimately benefits clinicians by offering a pragmatic, updated reference that balances therapeutic efficacy with economic sustainability.

23 October 2026 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
SNSurapon Nochaiwong
Surapon Nochaiwong
CRChidchanok Ruengorn
Chidchanok Ruengorn
PSPuckwipa Suwannaprom
Puckwipa Suwannaprom
KKKiatkriangkrai Koyratkoson
Kiatkriangkrai Koyratkoson
RARatanaporn Awiphan
Ratanaporn Awiphan
MCMati Chuamanochan
Mati Chuamanochan

2 June 2026 in Scientific Reports
Verified
Journal Article
Open access
TTThanphisit Trakarnvanich
Thanphisit Trakarnvanich
SNSurapon Nochaiwong
Surapon Nochaiwong
CRChidchanok Ruengorn
Chidchanok Ruengorn
KKKiatkriangkrai Koyratkoson
Kiatkriangkrai Koyratkoson
TNTanun Ngamvichchukorn
Tanun Ngamvichchukorn
To date, little is known regarding the treatment effects of different timed-dosing antihypertensive medications among hypertensive patients with albuminuria. We aimed to investigate whether morning or evening dosing of antihypertensive medication differentially affects early changes in albuminuria.We conducted an open-label, single-center, assessor-masked, parallel-group, pilot randomized controlled trial among adult hypertensive patients with albuminuria (urinary albumin‒creatinine ratio [UACR] ≥ 30 mg/g) receiving at least one antihypertensive medication. The participants were assigned (1:1) to receive antihypertensive medications either in the morning (6:00-10:00 AM) or in the evening (6:00-10:00 PM), with a treatment follow-up at 3 months. The primary outcome was the change in the log UACR. The secondary outcomes were changes in blood pressure and kidney function. Post hoc outcomes included clinically meaningful control of outcomes.Among the 60 participants enrolled (mean age, 65.6 years; proportion of females, 51.7%; median UACR, 116.1 mg/g), 58 patients completed the trial. The absolute changes in log UACR over 3 months were - 0.21 (95% CI, -0.40 to -0.03; n = 31) for morning-dosing and - 0.22 (95% CI, -0.46 to 0.01; n = 27) for evening-dosing, with an adjusted difference of -0.01 (95% CI, -0.32 to 0.30; P = 0.955) between the groups. No statistically significant difference was observed for secondary and post hoc outcomes. No safety profile concerns were identified. Among hypertensive patients with albuminuria, chronotherapy, whether administered in the morning or evening, did not affect early treatment outcomes in terms of the UACR, blood pressure, or kidney function. Trial registration: Thai Clinical Trials Registry (TCTR); TCTR20240930002; Registration date: 30/09/2024; retrospectively registered.